U.S. markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    60,554.78
    -1,085.84 (-1.76%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

New Strong Sell Stocks for September 13th

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:

Affimed N.V. AFMD is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 84.2% downward over the last 30 days.

DZS Inc. DZSI provides network access solutions and communications platforms. The Zacks Consensus Estimate for its current year earnings has been revised 13% downward over the last 30 days.

Esports Entertainment Group, Inc. GMBL is a licensed online gambling company. The Zacks Consensus Estimate for its current year earnings has been revised 1.9% downward over the last 30 days.

Nutriband Inc. NTRB is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.

Surface Oncology, Inc. SURF is a clinical-stage immuno-oncology company. The Zacks Consensus Estimate for its current year earnings has been revised 20.4% downward over the last 60 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Affimed N.V. (AFMD) : Free Stock Analysis Report
 
DZS Inc. (DZSI) : Free Stock Analysis Report
 
Surface Oncology, Inc. (SURF) : Free Stock Analysis Report
 
Esports Entertainment Group, Inc. (GMBL) : Free Stock Analysis Report
 
Nutriband Inc. (NTRB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research